| Literature DB >> 34187823 |
Trond Haugmark1,2, Kåre Birger Hagen3,4, Sella Aarrestad Provan3, Geir Smedslund3,4, Heidi A Zangi3,5.
Abstract
INTRODUCTION: Non-pharmacological approaches are recommended as first-line treatment for patients with fibromyalgia. This randomised controlled trial investigated the effects of a multicomponent rehabilitation programme for patients with recently diagnosed fibromyalgia in primary and secondary healthcare.Entities:
Keywords: primary care; rehabilitation medicine; rheumatology
Mesh:
Year: 2021 PMID: 34187823 PMCID: PMC8245472 DOI: 10.1136/bmjopen-2020-046943
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of patients. CBT, cognitive–behavioural therapy; FM, fibromyalgia.
Patients’ characteristics at baseline
| Variables | All | Intervention | Control | P value |
| Age, years, median (min, max) | 42 (24, 52) | 44 (26, 52) | 41 (24, 51) | 0.02* |
| Gender, women | 159 (94%) | 78 (92%) | 81 (95%) | 0.54† |
| Education | 0.60‡ | |||
| Primary/middle school (1–10 years) | 20 (12%) | 8 (9%) | 12 (14%) | |
| Upper secondary school/vocational 10–12 years | 68 (40%) | 36 (42%) | 32 (38%) | |
| Bachelor/university >12 years | 81 (48%) | 40 (47%) | 41 (48%) | |
| Work status | ||||
| Currently in paid work | 119 (70%) | 59 (69%) | 60 (71%) | 0.94‡ |
| Not in paid work | 48 (28%) | 24 (28%) | 24 (28%) | 0.94‡ |
| In paid work but on sick leave (100%) | 8 (17%) | 3 (13%) | 5 (21%) | |
| Work assessment allowance | 35 (73%) | 20 (83%) | 15 (62%) | |
| Unemployed | 4 (8%) | 1 (4%) | 3 (13%) | |
| Student | 1 (2%) | 1 (4%) | ||
| Married/living with partner | 120 (71%) | 54 (64%) | 66 (78%) | 0.06‡ |
| Symptoms duration, years, median, (min, max) | 8 (1, 32) | 10 (1, 32) | 7 (1, 30) | 0.05* |
| Comorbidities, median (min, max) | 2 (1, 6) | 2 (1, 6) | 2 (1, 6) | 0.24* |
| Smokers | 23 (14%) | 14 (17%) | 9 (11%) | 0.25‡ |
| FM in family | 57 (34%) | 27 (32%) | 30 (35%) | 0.55‡ |
| Use of medication in the last 3 months | ||||
| Pain medications | 149 (88%) | 73 (86%) | 76 (89%) | 0.64‡ |
| Hypnotics | 51 (30%) | 27 (32%) | 24 (28%) | 0.63‡ |
| Antidepressants | 20 (12%) | 8 (9%) | 12 (14%) | 0.48‡ |
| Anxiolytics | 8 (5%) | 2 (2%) | 6 (7%) | 0.28† |
Values are means (SD) or numbers (%).
*Mann-Whitney U test,
†Fisher’s exact test.
‡Pearson’s Χ2 test.
FM, fibromyalgia.
Figure 2The distribution of PGIC scores. PGIC, Patient Global Impression of Change.
Effect of intervention, primary outcome: Patient Global Impression of Change (PGIC)
| PGIC | 3 months | 12 months | P value | |||
| Intervention (n=76) | Control (n=84) | P value | Intervention (n=76) | Control (n=77) | ||
| Much better (scores 6 and 7), n (%) | 6 (7.9) | 4 (4.8) | 0.52* | 10 (13.2) | 6 (7.8) | 0.28† |
*Fisher’s exact test.
†Pearson’s Χ2 test.
Effects of intervention, secondary outcomes estimated by ANCOVA adjusted for baseline scores
| Intervention | Control | Baseline-adjusted mean difference (95% CI) | P value | |
| Pain (NRS 0–10, 0=no pain) | ||||
| Baseline | 6.7 (1.6) | 6.8 (1.9) | – | – |
| 3 months | 6.4 (1.7) | 6.6 (1.8) | 0.30 (−0.15 to 0.75) | 0.19 |
| 12 months | 5.8 (2.1) | 6.4 (1.8) | 0.55 (−0.00 to 1.11) | 0.05 |
| Fatigue (NRS 0–10, 0=no fatigue) | ||||
| Baseline | 7.5 (2.0) | 7.4 (2.0) | – | – |
| 3 months | 7.2 (1.9) | 7.1 (2.2) | −0.03 (−0.60 to 0.54) | 0.92 |
| 12 months | 6.8 (2.3) | 6.8 (2.3) | 0.12 (−0.56 to 0.80) | 0.72 |
| Sleep (NRS 0–10, 0=no sleep) | ||||
| Baseline | 6.8 (2.3) | 7.1 (2.5) | – | – |
| 3 months | 6.6 (2.5) | 6.9 (2.5) | 0.27 (−0.42 to 0.97) | 0.44 |
| 12 months | 6.5 (2.5) | 6.3 (2.5) | −0.24 (−0.99 to 0.50) | 0.52 |
| Psychological distress (GHQ-12, mean sum score, 0–36, 0=no distress) | ||||
| Baseline | 16.5 (6.6) | 19.2 (6.8) | – | – |
| 3 months | 13.4 (6.5) | 16.5 (7.0) | 1.57 (−0.37 to 3.50) | 0.11 |
| 12 months | 14.8 (6.8) | 16.6 (6.9) | 1.03 (−1.08 to 3.14) | 0.34 |
| Five Facet Mindfulness Questionnaire (mean sum score, 39–195, low to high) | ||||
| Baseline | 119 (17.2) | 113 (16.9) | – | – |
| 3 months | 124 (19.1) | 118 (16.3) | −1.07 (−4.73 to 2.58) | 0.56 |
| 12 months | 126 (17.6) | 118 (16.3) | −4.72 (−8.57 to −0.9) | 0.02 |
| Physical activity (0–15, 0=inactive) | ||||
| Baseline | 3.0 (2.4) | 2.8 (1.8) | – | – |
| 3 months | 2.3 (1.6) | 2.7 (1.9) | 0.53 (−0.04 to 1.10) | 0.07 |
| 12 months | 2.9 (2.3) | 2.8 (1.8) | 0.10 (−0.60 to 0.79) | 0.78 |
| Motivation and barriers for physical activity | ||||
| Self-efficacy (4–20, low to high) | ||||
| Baseline | 12.0 (2.9) | 12.0 (3.2) | – | – |
| 3 months | 12.5 (3.1) | 12.6 (3.1) | 0.08 (−0.70 to 0.86) | 0.84 |
| 12 months | 13.1 (3.5) | 12.8 (3.1) | −0.33 (−1.27 to 0.62) | 0.50 |
| Barriers (3–15, low to high) | ||||
| Baseline | 12.1 (2.4) | 12.1 (2.0) | – | – |
| 3 months | 11.8 (2.3) | 11.8 (1.9) | −0.00 (−0.48 to 0.47) | 0.99 |
| 12 months | 12.2 (2.4) | 12.2 (1.7) | −0.07 (−0.61 to 0.46) | 0.79 |
| Benefits (5–25, low to high) | ||||
| Baseline | 20.4 (3.2) | 21.1 (2.7) | – | – |
| 3 months | 20.3 (3.0) | 20.4 (2.7) | −0.19 (−0.89 to 0.50) | 0.59 |
| 12 months | 20.7 (3.0) | 20.1 (2.9) | −0.90 (−1.73 to −0.07) | 0.03 |
| Impact (8–40, low to high) | ||||
| Baseline | 28.8 (4.6) | 29.0 (4.8) | – | – |
| 3 months | 28.4 (4.8) | 28.5 (4.3) | 0.08 (−0.90 to 1.06) | 0.87 |
| 12 months | 28.9 (5.4) | 28.3 (4.6) | −0.49 (−1.63 to 0.65) | 0.40 |
| Work Productivity and Activity Impairment General Health | ||||
| Work impairment (0–10, 10=completely impaired) | ||||
| Baseline | 5.2 (2.5) | 6.2 (2.2) | – | – |
| 3 months | 5.1 (2.4) | 5.4 (2.5) | −0.15 (−1.05 to 0.76) | 0.75 |
| 12 months | 4.9 (3.2) | 5.3 (2.9) | 0.73 (−0.58 to 2.03) | 0.27 |
| Daily activity impairment (0–10, 10=completely impaired) | ||||
| Baseline | 7.0 (2.0) | 7.1 (1.9) | – | – |
| 3 months | 6.9 (1.7) | 6.7 (2.3) | −0.25 (−0.83 to 0.34) | 0.41 |
| 12 months | 6.3 (2.5) | 6.5 (2.2) | 0.07 (−0.65 to 0.79) | 0.84 |
| EQ-5D-5L | ||||
| Index (0–1, 1=perfect health) | ||||
| Baseline | 0.51 (0.2) | 0.47 (0.2) | – | – |
| 3 months | 0.55 (0.2) | 0.53 (0.2) | 0.02 (−0.05 to 0.09) | 0.86 |
| 12 months | 0.54 (0.2) | 0.50 (0.2) | 0.04 (−0.03 to 0.11) | 0.48 |
| VAS (0–100, 100=as good as it could be) | ||||
| Baseline | 44.6 (16.5) | 41.61 (17.0) | – | – |
| 3 months | 46.4 (16.1) | 51.5 (21.7) | −5.1 (−12.10 to 1.90) | 0.03 |
| 12 months | 49.0 (20.6) | 46.8 (18.5) | 2.19 (−4.67 to 9.05) | 0.77 |
ANCOVA, analysis of covariance; GHQ-12, General Health Questionnaire-12; NRS, Numerical Rating Scale; VAS, Visual Analogue Scale.